ALNY
Price
$454.80
Change
+$7.37 (+1.65%)
Updated
Sep 4, 01:45 PM (EDT)
Capitalization
58.65B
49 days until earnings call
DNLI
Price
$14.75
Change
-$0.56 (-3.66%)
Updated
Sep 4, 02:00 PM (EDT)
Capitalization
2.24B
56 days until earnings call
Interact to see
Advertisement

ALNY vs DNLI

Header iconALNY vs DNLI Comparison
Open Charts ALNY vs DNLIBanner chart's image
Alnylam Pharmaceuticals
Price$454.80
Change+$7.37 (+1.65%)
Volume$400
Capitalization58.65B
Denali Therapeutics
Price$14.75
Change-$0.56 (-3.66%)
Volume$510
Capitalization2.24B
ALNY vs DNLI Comparison Chart in %
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. DNLI commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a StrongBuy and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ALNY: $447.43 vs. DNLI: $15.31)
Brand notoriety: ALNY and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 116% vs. DNLI: 162%
Market capitalization -- ALNY: $58.65B vs. DNLI: $2.24B
ALNY [@Biotechnology] is valued at $58.65B. DNLI’s [@Biotechnology] market capitalization is $2.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 3 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • ALNY’s TA Score: 3 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than ALNY.

Price Growth

ALNY (@Biotechnology) experienced а -1.49% price change this week, while DNLI (@Biotechnology) price change was -1.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.72%. For the same industry, the average monthly price growth was +5.89%, and the average quarterly price growth was +27.73%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($58.6B) has a higher market cap than DNLI($2.24B). ALNY YTD gains are higher at: 90.145 vs. DNLI (-24.877). ALNY has higher annual earnings (EBITDA): -170.84M vs. DNLI (-521.52M). ALNY has more cash in the bank: 2.86B vs. DNLI (899M). DNLI has less debt than ALNY: DNLI (46.6M) vs ALNY (1.3B). ALNY has higher revenues than DNLI: ALNY (2.46B) vs DNLI (0).
ALNYDNLIALNY / DNLI
Capitalization58.6B2.24B2,617%
EBITDA-170.84M-521.52M33%
Gain YTD90.145-24.877-362%
P/E RatioN/AN/A-
Revenue2.46B0-
Total Cash2.86B899M318%
Total Debt1.3B46.6M2,783%
FUNDAMENTALS RATINGS
ALNY vs DNLI: Fundamental Ratings
ALNY
DNLI
OUTLOOK RATING
1..100
829
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
9100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3855
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5031

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (93) in the Biotechnology industry is in the same range as ALNY (96). This means that DNLI’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (9) in the Biotechnology industry is significantly better than the same rating for DNLI (100). This means that ALNY’s stock grew significantly faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as ALNY (100). This means that DNLI’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Price Growth Rating (38) in the Biotechnology industry is in the same range as DNLI (55). This means that ALNY’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as ALNY (100). This means that DNLI’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYDNLI
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
64%
Bearish Trend 16 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
60%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FKGRX147.410.59
+0.40%
Franklin Growth A
MWOKX67.110.25
+0.37%
MFS Global Growth R6
BFGFX50.71N/A
N/A
Baron Focused Growth Retail
GREYX9.32N/A
N/A
GuideStone Funds Global Rl Est Secs Inst
ARIDX6.15-0.01
-0.16%
AMG River Road Dividend All Cap Value I

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with IONS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
+0.10%
IONS - ALNY
56%
Loosely correlated
+5.22%
ARGX - ALNY
51%
Loosely correlated
+2.21%
INSM - ALNY
39%
Loosely correlated
-1.24%
DNLI - ALNY
39%
Loosely correlated
-0.91%
AXSM - ALNY
37%
Loosely correlated
-1.19%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.91%
NRIX - DNLI
58%
Loosely correlated
+3.84%
BEAM - DNLI
55%
Loosely correlated
+15.02%
OCUL - DNLI
54%
Loosely correlated
+1.89%
RGNX - DNLI
53%
Loosely correlated
+8.11%
IDYA - DNLI
52%
Loosely correlated
+1.10%
More